The
report " Hepatocellular Carcinoma Global Clinical Trials
Review, H1, 2016 ", has been prepared based on an in-depth
market analysis with inputs from industry experts.
GlobalData's
clinical trial report, Hepatocellular
Carcinoma Global
Clinical Trials Review, H1, 2016" provides an overview of
Hepatocellular Carcinoma clinical trials scenario. This report
provides top line data relating to the clinical trials on
Hepatocellular Carcinoma. Report includes an overview of trial
numbers and their average enrollment in top countries conducted
across the globe. The report offers coverage of disease clinical
trials by region, country (G7 & E7), phase, trial status, end
points status and sponsor type. Report also provides prominent drugs
for in-progress trials (based on number of ongoing trials).
GlobalData Clinical Trial Reports are generated using GlobalDatas
proprietary database - Pharma eTrack Clinical trials database.
Clinical trials are collated from 80+ different clinical trial
registries, conferences, journals, news etc across the globe.
Clinical trials database undergoes periodic update by dynamic
process.
The
report enhances the decision making capabilities and helps to create
an effective counter strategies to gain competitive advantage.
Download
Sample copy of this Report @
Scope
-
The report provides a snapshot of the global clinical trials
landscape
-
Report provides top level data related to the clinical trials by
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor
Type and End point status
-
The report reviews top companies involved and enlists all trials
(Trial title, Phase, and Status) pertaining to the company
-
The report provides all the unaccomplished trials (Terminated,
Suspended and Withdrawn) with reason for unaccomplishment
-
The Report provides enrollment trends for the past five years
-
Report provides latest news for the past three months
Reasons
to buy
-
Assists in formulating key business strategies with regards to
investment
-
Helps in identifying prominent locations for conducting clinical
trials which saves time and cost
-
Provides top level analysis of Global Clinical Trials Market which
helps in identifying key business opportunities
-
Supports understanding of trials count and enrollment trends by
country in global therapeutics market
-
Aids in interpreting the success rates of clinical trials by
providing a comparative scenario of completed and uncompleted
(terminated, suspended or withdrawn) trials
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level
Browse All reports Of this
Category: www.marketresearchreports.biz/category/38
Table
of Content :
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average
Enrollment by Country 8
Top Five Countries Contributing
to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing
to Clinical Trials in Europe 11
Top Countries Contributing to
Clinical Trials in North America 12
Top Five Countries Contributing
to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing
to Clinical Trials in Central and South America 14
Clinical Trials by G7
Countries: Proportion of Hepatocellular Carcinoma to Oncology
Clinical Trials 15
Clinical Trials by Phase in G7
Countries 16
Clinical Trials in G7 Countries
by Trial Status 17
Clinical Trials by E7
Countries: Proportion of Hepatocellular Carcinoma to Oncology
Clinical Trials 18
Clinical Trials by Phase in E7
Countries 19
Clinical Trials in E7 Countries
by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status
23
Clinical Trials by End Point
Status 24
Subjects Recruited Over a
Period of Time 25
Clinical Trials by Sponsor Type
26
Prominent Sponsors 27
Top Companies Participating in
Hepatocellular Carcinoma Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on
Hepatocellular Carcinoma 30
May 19, 2016: Incyte Highlights
Capmatinib Abstracts to be Presented at the 2016 ASCO Annual Meeting
30
May 18, 2016: Eli Lilly to
Present data on VEGF Receptor 2 antagonist ramucirumab at ASCO 30
May 18, 2016: Lilly to present
data on TGF small-molecule kinase inhibitor galunisertib at ASCO 31
May 12, 2016: CASI
Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2
Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 32
May 04, 2016: RedHill Biopharma
Announces National Cancer Institute Grant Supporting YELIVA Phase II
Hepatocellular Carcinoma Study 32
May 04, 2016: Phase III Trial
of Regorafenib in Patients with Unresectable Liver Cancer Meets
Primary Endpoint of Improving Overall Survival 33
Apr 26, 2016: Celsion Announces
Enrollment of First Patient in the OPTIMA Study in China 34
Apr 18, 2016: Onxeo Final Data
from Mechanistic Livatag Study Show Preferential Affinity for Liver,
Support Use as Advanced HCC Treatment 35
Apr 15, 2016: Conatus Poster at
EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer
Treatment 35
Apr 04, 2016: Onxeo announces
positive DSMB recommendation to continue Livatag ReLive study in HCC
36
Mar 29, 2016: SillaJen Enrolls
First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in
Advanced Liver Cancer 36
Mar 22, 2016: Daiichi Sankyo
and ArQule Announce Continuation of METIV-HCC Phase 3 Study of
Tivantinib in Second-Line Hepatocellular Carcinoma 37
Mar 16, 2016: Onxeo Poster
Demonstrating Unique Livatag Mechanism of Action Accepted for
Presentation at AACR Annual Meeting 37
Mar 07, 2016: Major Liver
Cancer Study Completes Palliative Cohort Enrolment 38
Mar 07, 2016: Celsion Announces
Launch of the OPTIMA Study in China 38
Clinical Trial Profile
Snapshots 40
Appendix 1044
Abbreviations 1044
Definitions 1044
Research Methodology 1045
Secondary Research 1045
About GlobalData 1046
Contact Us 1046
Disclaimer 1046
Source 1047
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
Mr.
Nachiket
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment